Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

FDA Regulations Reform? Risks and Benefit for the Approval Process of New Drugs

Posted on June 2nd, 2017 by in Pharma R&D

Know the rules

Since 1906, the US Food and Drug Administration (FDA) through regulations has been responsible for ensuring the approval of new drugs whose health benefits outweigh the known risks associated with the drug.

Continue reading “FDA Regulations Reform? Risks and Benefit for the Approval Process of New Drugs” »

Predicting Adverse Event Risks and Gaining Insights from Disparate Data

Posted on May 17th, 2017 by in Pharma R&D

The upcoming Bio IT World Conference and Expo will feature two talks from Elsevier Life Sciences consultants, focusing on predicting adverse events in clinical trials and extracting knowledge from multiple data sets. Continue reading “Predicting Adverse Event Risks and Gaining Insights from Disparate Data” »

Cost Saving: The trade-off that bites back

Posted on April 3rd, 2017 by in Pharma R&D

Making a trade-off between competing activities or priorities is a critical skill involved in developing a new medicine. This approach helps balance the risk of technical failure and investment to develop innovative products, an important consideration with such high failure rates in pharma R&D. Continue reading “Cost Saving: The trade-off that bites back” »

Start-Up Spotlight: CuroNZ Ltd

Posted on March 3rd, 2017 by in Pharma R&D

In Auckland, New Zealand, one biotech start-up has set its sights on research that can advance the treatment of diseases of the central nervous system. That company is CuroNZ, and Chief Scientist and Managing Director Dr. Frank Sieg describes their excellent progress so far, and what’s ahead. Continue reading “Start-Up Spotlight: CuroNZ Ltd” »

  1. 1
  2. 2
  3. 3
  4. 4